Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — TSN - ASX Gems Conference (December 2025)
9 slides from Proteomics International Laboratories's conference presentation, Dec 19, 2025
Slide 1: Proteomics International: Precision diagnostics: Commercial Launch
Proteomics International LABORATORIES LTD TSN - ASX Gems Conference Healthcare Spotlight Precision diagnostics: Commercial Launch 19 December 2025 Dr. Richard Lipscombe Managing Director
Slide 2: Forward Looking Statements
ASX: PIQ Forward Looking Statements This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or thei
Slide 3: Proteomics International Key Highlights
ASX: PIQ Proteomics International Key Highlights Launching four Tests validated in large first-in-class diagnostics Large addressable markets clinical studies on two continents in FY26 with significant unmet medical needs Significant advantages over current Standards-of-Care OxiDx Funded to execute
Slide 4: Problem & Solution: a suite of novel diagnostic tests
ASX: PIQ Problem & Solution: a suite Targeting major diseases which are currently detected late → existing outcomes are poor for of novel diagnostic tests patients & cost healthcare system billions of dollars • A novel and accurate blood test for predicting the onset of chronic kidney disease in typ
Slide 5: Market Launch: Ramp Up → Partnering
ASX: PIQ Market Launch: Drive near-term revenue with maximum optionality for strategic partnering Ramp Up → Partnering Focus on market Grow sales via Demonstrate market awareness and strategic partnerships adoption and sales launch of tests ✓ Developed suite of highly accurate, ✓ Engagement with GP
Slide 6: Milestones: multiple value drivers achieved & ahead
Milestones: ASX: PIQ multiple value drivers achieved & ahead Q1 Q2 Q3 Q4 Milestone TARGET QTR FY25 FY26 FY26 FY26 FY26 Impact Commercial Australian lab certified for clinical testing ✓ Basis for all Promarker tests to be run clinically US Reference Lab established ✓ Key to first US sales and reimbur
Slide 7: Corporate Overview
ASX: PIQ Corporate Financial and Corporate Overview • Strong Capital position ➢ $12M capital raise completed May 2025 comprising $4.5M Corporate Snapshot Institutional & Director placement + $7.5M oversubscribed SPP ASX code PIQ ➢ Funded to execute launch strategies Market Capitalisation (10 Dec 202
Slide 8: Investment Summary
ASX: PIQ Investment Summary • Commercialising x4 first-in-class blood tests for major diseases and conditions with significant unmet need • Ramp-up phase for PromarkerD & PromarkerEso with first sales already achieved • Commercial platform developed to drive awareness for each test in Australia and
Slide 9: Contact
ASX:PIQ ASX: PIQ Contact Dr Richard Lipscombe Dirk van Dissel Managing Director Investor Relations & Corporate Advisory T: +61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au 9
Proteomics International Laboratories — TSN - ASX Gems Conference (December 2025) on 6ix